Zhejiang Shengda Bio-Pharm Co., Ltd. Class A

Zhejiang Shengda Bio-Pharm Co., Ltd. Class A

SSSE:603079
10.96
CNY
-0.23
(-2.06%)
0.23EPS
75.16P/E
2.57BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
3.62
3.24
4.58
4.12
3.9
3.16
3.31
5.14
4.59
4.22
4.31
4.78
4.76
4.36
Basic EPS, GAAP
0.49
0.37
0.74
0.52
0.56
0.29
0.3
1.17
0.44
0.18
-0.32
0.17
0.35
0.18
Free Cash Flow per Basic Share
- -
0.1
1.08
0.16
0.37
-0.36
-0.81
1.47
-0.15
-0.13
-1.07
-0.13
-0.04
- -
Dividend per Share
0.72
0.05
0.05
0.03
0.5
0.17
0.14
0.11
0.38
0.16
0.08
0.1
0.04
0.15
Book Value per Share
2.39
2.76
3.73
3.74
4.9
5.05
5.64
7.62
7.71
7.76
7.33
7.37
8.38
8.37
Tangible Book Value per Share
1.38
1.81
2.59
2.65
4.14
4.16
4.45
6.59
6.74
6.42
5.91
5.98
7.15
7.26
Basic Weighted Avg Shares
110
118
117
117
130
156
157
169
172
175
169
173
178
187
Sales/Revenue/Turnover
399
381
536
482
509
493
519
867
790
738
727
827
845
816
Operating Margin (%)
14.11
15.19
22.4
11.75
20.36
11.85
13.67
32.44
9.65
3.01
-0.38
6.29
10
8.89
Depreciation Expense
- -
25
27
27
28
33
52
70
71
68
73
75
77
- -
Net Income, GAAP
55
44
87
61
73
45
47
197
76
31
-54
29
62
34
Effective Tax Rate (%)
14.84
12.52
19.81
16.51
15.54
18.73
23.22
15.07
10.27
16.66
- -
24.1
13.56
21.65
Profit Margin (%)
13.69
11.5
16.16
12.64
14.28
9.04
9.06
22.76
9.59
4.27
-7.43
3.56
7.36
4.16
Working Capital
50
16
115
115
401
153
349
522
506
485
400
457
764
771
LT Debt
38
16
- -
28
- -
5
244
1
1
- -
144
231
318
348
Total Equity
281
325
439
440
769
828
912
1,325
1,337
1,343
1,270
1,284
1,615
1,619
Return on Invested Capital (%)
10.9
10.43
18.83
10.21
10.63
4.74
3.5
15.43
4.93
2.09
- -
2.32
3.98
2.26
Return on Capital (%)
17.06
11.63
19.84
12.66
11.29
5.75
5.82
15.45
5.78
2.53
- -
1.52
3.2
1.49
Return on Common Equity (%)
25.09
14.45
22.7
13.86
12.01
5.71
5.62
18.04
5.77
2.38
-4.19
2.34
4.37
2.16

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
4
8
9
LT Borrowings
331
331
347
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
189
189
189
Market Capitalization
3,159
2,140
2,573

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
986
1,048
1,063
Cash, Cash Equivalents & STI
603
584
589
Accounts Receivable, Net
129
149
144
Inventories
220
222
238
Total Current Liabilities
210
295
292
Payables & Accruals
- -
- -
- -
ST Debt
4
8
9
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
16.09%
4.56%
25.77%
Free Cash Flow
11.15%
85.27%
-69.05%
Net Income, GAAP
-15.88%
-86.99%
111.24%
Sales/Revenue/Turnover
6.36%
-0.22%
2.07%
Total Cash Common Dividend
155.59%
22.45%
-56.76%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
185
200
224
219
827
2025
203
198
- -
223
845
2026
189
200
204
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.02
0.07
0.03
0.05
0.17
2025
0.13
0.09
- -
0.05
0.35
2026
0.07
0.04
0.02
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
0.08
0.01
0.01
0.1
2025
0.01
0.01
- -
0.01
0.04
2026
0.01
0.06
0.06
- -
- -

Company Description

CEO
Chao Liang
Full Time Employees
1,083
Sector
Health technology
Industry
Pharmaceuticals: major
Address
No. 789, Renmin East Road Taizhou ZH China 317200
IPO Date
Aug 23, 2017
Business
Zhejiang Shengda Bio-Pharm Co., Ltd. (603079.SS) develops, produces and sells food and feed additives for the pharmaceutical, nutritional, food and animal feed industries; its core vitamin products include biotin and folic acid, while its Silver-Elephant Bio-engineering Co., Ltd. subsidiary manufactures biological preservatives such as nisin and natamycin, alongside intermediate active pharmaceutical ingredients (APIs). The company, founded in 1999 and headquartered at No. 789 Renmin East Road, Tiantai, Zhejiang, China, operates primarily in China with exports to global markets and adheres to GMP standards, holding certifications including ISO22000, BRC, FAMI-QS and OHSAS18001; it maintains a provincial high-tech R&D center, Academician Workstation and strong research capabilities in vitamin B group products and bio-preservatives, supported by talents from Zhejiang and National Thousand Talents Programs. In recent developments, the company completed non-trading transfers under its 2024 Employee Stock Ownership Plan in October 2025, received funding from Tibet Xingrui Enterprise Management Partnership and pursued forward integration by elevating biotin and folic acid into higher-end pharmaceutical API markets, including obtaining CEP certification for biotin and achieving substantial sales growth in CEP biotin and API folic acid during 2022 that continued to shape its strategic focus.